<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD07170000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>Q00987</UniProt_ID>
  <Seq_Length>491</Seq_Length>
  <Molecule_Weight>55233</Molecule_Weight>
  <KEGG_ID>hsa:4193</KEGG_ID>
  <Orthology_ID>K06643</Orthology_ID>
  <EBI_ID>EBI-389668</EBI_ID>
  <Function_Summary>E3 ubiquitin-protein ligase that mediates ubiquitination of p53/TP53, leading to its degradation by the proteasome. Inhibits p53/TP53- and p73/TP73-mediated cell cycle arrest and apoptosis by binding its transcriptional activation domain. Also acts as an ubiquitin ligase E3 toward itself and ARRB1. Permits the nuclear export of p53/TP53. Promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma RB1 protein. Inhibits DAXX-mediated apoptosis by inducing its ubiquitination and degradation. Component of the TRIM28/KAP1-MDM2-p53/TP53 complex involved in stabilizing p53/TP53. Also component of the TRIM28/KAP1-ERBB4-MDM2 complex which links growth factor and DNA damage response pathways. Mediates ubiquitination and subsequent proteasome degradation of DYRK2 in nucleus. Ubiquitinates IGF1R and promotes it to proteasomal degradation.</Function_Summary>
  <Pfam_ID>PF02201:SWIB@@PF00641:zf-RanBP</Pfam_ID>
  <Allosteric_Activator_Count>0</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>0</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>0</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>Hdm2</Alias>
      <Alias>p53-binding protein Mdm2</Alias>
      <Alias>Double minute 2 protein</Alias>
      <Alias>Oncoprotein Mdm2</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Catalysis of the joining of two substances, or two groups within a single molecule, with the concomitant hydrolysis of the diphosphate bond in ATP or a similar triphosphate.</Detail>
      <Keyword>Ligase activity</Keyword>
      <Ontology_ID>GO:0016874</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with one of the p53 family of proteins.</Detail>
      <Keyword>P53 binding</Keyword>
      <Ontology_ID>GO:0002039</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the reaction: ATP + ubiquitin + protein lysine = AMP + diphosphate + protein N-ubiquityllysine.</Detail>
      <Keyword>Ubiquitin-protein ligase activity</Keyword>
      <Ontology_ID>GO:0004842</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with zinc (Zn) ions.</Detail>
      <Keyword>Zinc ion binding</Keyword>
      <Ontology_ID>GO:0008270</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with any enzyme.</Detail>
      <Keyword>Enzyme binding</Keyword>
      <Ontology_ID>GO:0019899</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with any metal ion.</Detail>
      <Keyword>Metal ion binding</Keyword>
      <Ontology_ID>GO:0046872</Ontology_ID>
    </Funtion>
  </Function_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptosis.</Detail>
      <Keyword>Negative regulation of apoptosis</Keyword>
      <Ontology_ID>GO:0043066</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The modification of peptidyl-lysine.</Detail>
      <Keyword>Peptidyl-lysine modification</Keyword>
      <Ontology_ID>GO:0018205</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Protein involved in ubiquitin-like modifier processing, activation, conjugation or deconjugation such as Ubl-activating enzymes (E1s), Ubl-conjugating enzymes (E2s), Ubl-protein ligases (E3s), some thiol proteases (Ubiquitin carboxyl-terminal hydrolases (UCH), Ubiquitin-specific processing proteases (UBP) and ubiquitin-like proteases) and the ubiquitin-like modifier proteins. Besides signaling proteolysis, ubiquitination for example can be a signal for trafficking, kinase activation and other nonproteolytic fates.</Detail>
      <Keyword>Ubl conjugation pathway</Keyword>
      <Ontology_ID>KW-0833</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of the cascade of processes induced by the cell cycle regulator phosphoprotein p53, or an equivalent protein, in response to the detection of DNA damage.</Detail>
      <Keyword>Negative regulation of DNA damage response, signal transduction by p53 class mediator</Keyword>
      <Ontology_ID>GO:0043518</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process of communication from a neuron to a target (neuron, muscle, or secretory cell) across a synapse.</Detail>
      <Keyword>Synaptic transmission</Keyword>
      <Ontology_ID>GO:0007268</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The aggregation, arrangement and bonding together of a set of components to form a protein complex.</Detail>
      <Keyword>Protein complex assembly</Keyword>
      <Ontology_ID>GO:0006461</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A process in which a protein is transported to, or maintained in, a location within the nucleus.</Detail>
      <Keyword>Protein localization to nucleus</Keyword>
      <Ontology_ID>GO:0034504</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that decreases the rate, frequency, or extent of cell cycle arrest, the process in which the cell cycle is halted during one of the normal phases.</Detail>
      <Keyword>Negative regulation of cell cycle arrest</Keyword>
      <Ontology_ID>GO:0071157</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The series of molecular signals generated as a consequence of the nerve growth factor receptor binding to one of its physiological ligands.</Detail>
      <Keyword>Nerve growth factor receptor signaling pathway</Keyword>
      <Ontology_ID>GO:0048011</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating lowered oxygen tension. Hypoxia, defined as a decline in O2 levels below normoxic levels of 20.8 - 20.95%, results in metabolic adaptation at both the cellular and organismal level.</Detail>
      <Keyword>Cellular response to hypoxia</Keyword>
      <Ontology_ID>GO:0071456</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the rate or extent of cell proliferation.</Detail>
      <Keyword>Positive regulation of cell proliferation</Keyword>
      <Ontology_ID>GO:0008284</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A series of molecular signals in which a cell uses a phosphatidylinositol-mediated signaling to convert a signal into a response. Phosphatidylinositols include phosphatidylinositol (PtdIns) and its phosphorylated derivatives.</Detail>
      <Keyword>Phosphatidylinositol-mediated signaling</Keyword>
      <Ontology_ID>GO:0048015</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The series of molecular signals generated as a consequence of a fibroblast growth factor receptor binding to one of its physiological ligands.</Detail>
      <Keyword>Fibroblast growth factor receptor signaling pathway</Keyword>
      <Ontology_ID>GO:0008543</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of the breakdown of a protein or peptide by hydrolysis of its peptide bonds, initiated by the covalent attachment of ubiquitin, and mediated by the proteasome.</Detail>
      <Keyword>Positive regulation of proteasomal ubiquitin-dependent protein catabolic process</Keyword>
      <Ontology_ID>GO:0032436</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The series of molecular signals generated as a consequence of an epidermal growth factor receptor binding to one of its physiological ligands.</Detail>
      <Keyword>Epidermal growth factor receptor signaling pathway</Keyword>
      <Ontology_ID>GO:0007173</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of transcription from an RNA polymerase II promoter.</Detail>
      <Keyword>Negative regulation of transcription from RNA polymerase II promoter</Keyword>
      <Ontology_ID>GO:0000122</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process in which an organism has an effect on an organism of a different species.</Detail>
      <Keyword>Interspecies interaction between organisms</Keyword>
      <Ontology_ID>GO:0044419</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that decreases the stability of a protein, making it more vulnerable to degradative processes or aggregation.</Detail>
      <Keyword>Protein destabilization</Keyword>
      <Ontology_ID>GO:0031648</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A cascade of processes induced by the cell cycle regulator phosphoprotein p53, or an equivalent protein, in response to the detection of DNA damage and resulting in the stopping or reduction in rate of the cell cycle.</Detail>
      <Keyword>DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest</Keyword>
      <Ontology_ID>GO:0006977</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the rate or extent of progression through the mitotic cell cycle.</Detail>
      <Keyword>Positive regulation of mitotic cell cycle</Keyword>
      <Ontology_ID>GO:0045931</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an antibiotic stimulus. An antibiotic is a chemical substance produced by a microorganism which has the capacity to inhibit the growth of or to kill other microorganisms.</Detail>
      <Keyword>Response to antibiotic</Keyword>
      <Ontology_ID>GO:0046677</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The directed movement of a protein to a specific location.</Detail>
      <Keyword>Establishment of protein localization</Keyword>
      <Ontology_ID>GO:0045184</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process in which a ubiquitin group, or multiple groups, are covalently attached to the target protein, thereby initiating the degradation of that protein.</Detail>
      <Keyword>Protein ubiquitination involved in ubiquitin-dependent protein catabolic process</Keyword>
      <Ontology_ID>GO:0042787</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <PTM_List>
    <PTM>
      <Position>166</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
  </PTM_List>
  <Molecule_Seq>
    <Protein_Seq>MCNTNMSVPTDGAVTTSQIPASEQETLVRPKPLLLKLLKSVGAQKDTYTMKEVLFYLGQYIMTKRLYDEKQQHIVYCSNDLLGDLFGVPSFSVKEHRKIYTMIYRNLVVVNQQESSDSGTSVSENRCHLEGGSDQKDLVQELQEEKPSSSHLVSRPSTSSRRRAISETEENSDELSGERQRKRHKSDSISLSFDESLALCVIREICCERSSSSESTGTPSNPDLDAGVSEHSGDWLDQDSVSDQFSVEFEVESLDSEDYSLSEEGQELSDEDDEVYQVTVYQAGESDTDSFEEDPEISLADYWKCTSCNEMNPPLPSHCNRCWALRENWLPEDKGKDKGEISEKAKLENSTQAEEGFDVPDCKKTIVNDSRESCVEENDDKITQASQSQESEDYSQPSTSSSIIYSSQEDVKEFEREETQDKEESVESSLPLNAIEPCVICQGRPKNGCIVHGKTGHLMACFTCAKKLKKRNKPCPVCRQPIQMIVLTYFP</Protein_Seq>
    <DNA_Seq>GCACCGCGGCGAGCTTGGCTGCTTCTGGGGCCTGTGTGGCCCTGTGTGTCGGAAAGATGGAGCAAGAAGCCGAGCCCGAGGGGCGGCCGCGACCCCTCTGACCGAGATCCTGCTGCTTTCGCAGCCAGGAGCACCGTCCCTCCCCGGATTAGTGCGTACGAGCGCCCAGTGCCCTGGCCCGGAGAGTGGAATGATCCCCGAGGCCCAGGGCGTCGTGCTTCCGCGCGCCCCGTGAAGGAAACTGGGGAGTCTTGAGGGACCCCCGACTCCAAGCGCGAAAACCCCGGATGGTGAGGAGCAGGCAAATGTGCAATACCAACATGTCTGTACCTACTGATGGTGCTGTAACCACCTCACAGATTCCAGCTTCGGAACAAGAGACCCTGGTTAGACCAAAGCCATTGCTTTTGAAGTTATTAAAGTCTGTTGGTGCACAAAAAGACACTTATACTATGAAAGAGGTTCTTTTTTATCTTGGCCAGTATATTATGACTAAACGATTATATGATGAGAAGCAACAACATATTGTATATTGTTCAAATGATCTTCTAGGAGATTTGTTTGGCGTGCCAAGCTTCTCTGTGAAAGAGCACAGGAAAATATATACCATGATCTACAGGAACTTGGTAGTAGTCAATCAGCAGGAATCATCGGACTCAGGTACATCTGTGAGTGAGAACAGGTGTCACCTTGAAGGTGGGAGTGATCAAAAGGACCTTGTACAAGAGCTTCAGGAAGAGAAACCTTCATCTTCACATTTGGTTTCTAGACCATCTACCTCATCTAGAAGGAGAGCAATTAGTGAGACAGAAGAAAATTCAGATGAATTATCTGGTGAACGACAAAGAAAACGCCACAAATCTGATAGTATTTCCCTTTCCTTTGATGAAAGCCTGGCTCTGTGTGTAATAAGGGAGATATGTTGTGAAAGAAGCAGTAGCAGTGAATCTACAGGGACGCCATCGAATCCGGATCTTGATGCTGGTGTAAGTGAACATTCAGGTGATTGGTTGGATCAGGATTCAGTTTCAGATCAGTTTAGTGTAGAATTTGAAGTTGAATCTCTCGACTCAGAAGATTATAGCCTTAGTGAAGAAGGACAAGAACTCTCAGATGAAGATGATGAGGTATATCAAGTTACTGTGTATCAGGCAGGGGAGAGTGATACAGATTCATTTGAAGAAGATCCTGAAATTTCCTTAGCTGACTATTGGAAATGCACTTCATGCAATGAAATGAATCCCCCCCTTCCATCACATTGCAACAGATGTTGGGCCCTTCGTGAGAATTGGCTTCCTGAAGATAAAGGGAAAGATAAAGGGGAAATCTCTGAGAAAGCCAAACTGGAAAACTCAACACAAGCTGAAGAGGGCTTTGATGTTCCTGATTGTAAAAAAACTATAGTGAATGATTCCAGAGAGTCATGTGTTGAGGAAAATGATGATAAAATTACACAAGCTTCACAATCACAAGAAAGTGAAGACTATTCTCAGCCATCAACTTCTAGTAGCATTATTTATAGCAGCCAAGAAGATGTGAAAGAGTTTGAAAGGGAAGAAACCCAAGACAAAGAAGAGAGTGTGGAATCTAGTTTGCCCCTTAATGCCATTGAACCTTGTGTGATTTGTCAAGGTCGACCTAAAAATGGTTGCATTGTCCATGGCAAAACAGGACATCTTATGGCCTGCTTTACATGTGCAAAGAAGCTAAAGAAAAGGAATAAGCCCTGCCCAGTATGTAGACAACCAATTCAAATGATTGTGCTAACTTATTTCCCCTAGTTGACCTGTCTATAAGAGAATTATATATTTCTAACTATATAACCCTAGGAATTTAGACAACCTGAAATTTATTCACATATATCAAAGTGAGAAAATGCCTCAATTCACATAGATTTCTTCTCTTTAGTATAATTGACCTACTTTGGTAGTGGAATAGTGAATACTTACTATAATTTGACTTGAATATGTAGCTCATCCTTTACACCAACTCCTAATTTTAAATAATTTCTACTCTGTCTTAAATGAGAAGTACTTGGTTTTTTTTTTTCTTAAATATGTATATGACATTTAAATGTAACTTATTATTTTTTTTGAGACCGAGTCTTGCTCTGTTACCCAGGCTGGAGTGCAGTGGCGTGATCTTGGCTCACTGCAAGCTCTGCCTCCCGGGTTCGCACCATTCTCCTGCCTCAGCCTCCCAATTAGCTTGGCCTACAGTCATCTGCCACCACACCTGGCTAATTTTTTGTACTTTTAGTAGAGACAGGGTTTCACCGTGTTAGCCAGGATGGTCTCGATCTCCTGACCTCGTGATCCGCCCACCTCGGCCTCCCAAAGTGCTGGGATTACAGGCATGAGCCACCGCGTCCGGCCTAAATGTCACTTAGTACCTTTGATATAAAGAGAAAATGTGTGAAAGATTTAGTTTTTTGTTTTTTTGTTTGTTTGTTTGTTTGTTTGTTTTGAGATGAGTCTCTCTGTCGCCCAGGCTGGAGTGCAGTGTCATGATCTAGCAGTCTCCGCTTCCCGGGTTCAAGCCATTCTCCTGGCTCAGCCTCTGGAGCAGCTGGGATTACAGGCATGCACCACCATGCCCAGCTAATTTTTGTATTTTTAGTAGAGATAGGGTTTCACCATGTTGGCCAGGCTGGTCACGAACTCCTGACCTCAAGTGAGGTCACCCGCCTCGGCCTCCCGAAGTGCTGGGATTGCAGATGTGAGCCACCATGTCCAGCCAAGAATTAGTATTTAAATTTTAGATACTCTTTTTTTTTTTTTTTTTTTTTTTTTTTGAGACAGAGTCTTGCTCCATCACCCATGCTAGAGTGCAGTGGAGTGATCTCGGCTCACTGCAACTTCCGCCTTCTGGGTTCAAGCTATTCTCCTGCCTCAGCCTTCCAAGTAACTGGGATTACAGGCATGTACCACCATACCAGCTGATTTTTTTGTATTTTTAGTAAAGACAGGGTTTCACCATGTTAGCCAGGCTGATCTTGAACTCCTAAACTCAAGTGATCTACTCACCTCAGCCTCCCAAAATGCTGGGATTACAGATGTGAGGCACCTGGCCTCAGATTTTTGATACTCTTAAACCTTCTGATCCTTAGTTTCTCTCTCCAAAATACTCTTTCTAGGTTAAAAAAAAAAAGGCTCTTATATTTGGTGCTATGTAAATGAAAATGTTTTTTAGGTTTTCTTGATTTAACAATAGAGACAGGGTCTCCCTGTGTTGCCCAGGCTGGTCTCGAACTCCTGGGCTCAAGAGATCCTCCTGTCTTGGCCTCGCAAAGTGCTAAGTAGGATTACAGGCGTTAGCCACCACACCCGGCTGTAAAAATGTACTTATTCTCCAGCCTCTTTTGTATAAACCATAGTAAGGGATGGGAGTAATGATGTTATCTGTGAAAATAGCCACCATTTACCCGTAAGACAAAACTTGTTAAAGCCTCCTGAGTCTAACCTAGATTACATCAGGCCCTTTTTCACACACAAAAAAATCCTTTATGGGATTTAATGGAATCTGTTGTTTCCCCCTAAGTTGAAAAACAACTCTAAGACACTTTAAAGTACCTTCTTGGCCTGGGTTACATGGTTCCCAGCCTAGGTTTCAGACTTTTGCTTAAGGCCAGTTTTAGAAACCCGTGAATTCAGAAAAGTTAATTCAGAAATTTGATAAACAGAATTGTTATTTAAAAACTAACTGGAAAGATTGTTAAGTTCTTTCTGAATTATTCAGAAATTATGCATCATTTTCCTTCAAGAATGACAGGGTCAGCATGTGGAATTCCAAGATACCTCTTGACTTCCTCTCAAGCTCCGTGTTTGGTCAGTGGAGGCCCATCCGAGCTCAGCACTGAGAAGTGTTAGTTTCTTTGGGACCCATCTACCCTGACCACATCATGATGTTCATCTGCAGCTGTTGCAAGGTGTTCAGATTGTATAAACATAAATGTCACAAAAACTTTAAAAGAAGTGCAATTCTCAAAAGGTTAGGTGGACTAAAGCATTCTGTAAAGCAACTGCTAATAATGAGCTTACAGTGGATTTGAATTTGAAAAATATAGTAACAAGCCTGTCAAATATCTGCAAGAACTATGGAATAAAACTACTGATGCAGTGAAGACAGTTGAAAAGATCAAACAAATGCCAAGCTATATTTATAATGAACAAATTCAAGAAAAAGGACTACGGAAAGTTCAGGACATCAAAGAAGTCAGGCAAAACTCATCTTGACCCCTGTTGCAGGCAAAGGAACGCAGCTGGAAGAAAAGATGATATAACAGTTAACAGGATGCAGACATGGCAGAGGTTTCCTAAAAATCTCATTATCTATAACCATTTCTATATTTACATTTGAAAATCTCCTTTGGAGACTTAGAACCTCTAAATTATTGACTTATTTTTTATATAAGGTCACTCCGATGAAAGGTGATTACAAAATCATCTACATTGCTGTCTACAAAACAGATAATATGGATGTTTGATCGCATCTCATTGTTAACTCTTTACTGATATGTTTGTAAATACAGAAGTGAAATGTGGACATAAAATAGTTACGCTATTTGGTTAATGGTACTAGACAACATGTAATTAATGACATTCAAAAATTTATGGCTAGTGATATATATAAAGTAAAATTTTCTTTGCAGTAAAATATGCCCTTTATTATAGAAGGGAGGATATAAGGAACCAACAGTTTGTATGAAAATAGCTCAAATAATATCTTTTATTTTGATTTTAATATTTCTTATTTTGGTTTATTAGTGTCTTAGAACAAAATGGCCTTATATAATGAAGCCTAGTTATGCTGGACTGTTTTGATCTCTTTTAATTGTTCTGACAGATAGTTGGGGATGAGAGCCGAATAAGGTTTGCCTGAAATAACTGACACTATATAATTTCTGCTTTGGCAAATACTAAGTTCTAACTTGTCATTCCTGGTAGAACAAGCTTTATTTTTCGAGCCTAGCAATGATCTAGAAGCAGATGTTATCTCAGTGCCTTTTGCAATTTGTTGTGTGGGTTTTTTTTTTTTTAAAGCCACACAATAATTTTGGAAAACAATGTATGGGTAGAACATGTGTCTGTTAATTGCACACAAAACCACTTTTAATGGGTACAGAGTTAAATTTGAAGGAATAAGTTCTAGCTGAAGTATTATGAACTCCAAATAATGCTTTGAGGACCTCCAAAGGTAAAAGTACTAATCCCTTTGGCCATTTATTGAGAGAGAGAGAGAGAGAGAGTAGGGTGACTATAGTTAATGTATTGAATGTTCTTGCTACAAATAAATGATATTTGAGCTGATGGGTGTGCTAATTACACTGATTTGATCAATACCCATTGTATGTGAAACAGTACATACACCATATTTACAATTATGTATTTAACATTTAAAATTTCTAATATAAGTATCTCTCAAACTGTGGATTAACTTCTTGATTTATATTTAAATATGAATCTTAAGCAAAACAGTGAAAATAACCATCTTGATTTAGTGTTTTTCTCCCATATGTGAATTGTATATACTTAGGTGAAGACAATAAAATCAACTGAACTGTAAGCTTAGAATAGGACTGAGGTAATTCTGCACAGCAACTTTACTAATGGTACATTGTTGCTTCAAAACTCTCTCTCTCTCTCTCTGTCTGTCTCAATAAATGGCCAAAGGGATTAGTAGTTTACCTGTGGAGGTCCTCCAAGCATTATTTGGAGTTGATAATACTTCAGCTACAACCAAGCAGAATCTCTTTTTTTTGGAGGTCCTCGAAGCATTATTTGGAGTTGATAATACTTCAGCTTCAATTTGGAGTTGATAATATTTCAGCTAGAACCTAGTAGAATCTGTTTTTTTCCTTTGGAGGTCCTCAAAGCATTATTGGAGTTCATAATACTGAAGCTAGAACCAAGCAGAATCTGTTTTTTTCTGAGGAGTATCGGTAGCATAAATGTGATTATAAACATAGTACACTTGATATATGGAGGCAGTGACAGCTATTTTTACAAAATTTAAATCTGCAAATGGATTCAACATGTTTATGGGTTATTAAAATTGTCTGATTTCTTAGGTTCTTTATAGTACACGTGTTGAAAATAAATGATTAAGAATTGTTTCAAGAATGCAATTATTTGATCTTAAATTTTTATGAGTTGTTAAAATAGAAATTATTTGAATATCATATATTTGGGTAACAAAAGGCACAAGTCTGAATGTGTTTCTTTTTCTGGAATGGCCATGCCTGCCCACTTTAGAAATACAAATATCACTGGGCAGCTTGAAGCAGTTGGGAGCCTCCAATGAGAGCAACTTGAGAGAATGATGTTGCAAGTTAGTAGGAGTAAGAAATGCTGTGTTCTCCCTGTCTTCTCTTAGGTCACATGGCAGCCTGGCCTAAGTGATCGTGAATGGTCTATAAGGGAGGTAGCTGGGACAGGGAGGGGAGTTTGGGCTAGCCACCGTACCACTTGTCAGCGTGAAAAGTAAGATTGTAATTGCCTGTTTAGTTTTCTGCCTCATCTTTGAAAGTTCCACCAAGCTGGGAACCTCTTGATTGTGAGGCACAAATGTAAGTACATCAGAAAAAAACAAAAAAACTGGCTTTAAAGCAGGAGCTTGTGGGCCCCTAAGCCAGACGGGGACTAGCTTTTGGCATTATATAATTAAGATTTTTTAAATCCTTAATAAGGGTTTTATTTTATTTTTATTTATTTTTTGAGACGGAGTCTTGCTCTGTGGCTCAGGCTGGAGTACAGTGGTGCAATCTTGGCTCACTGCAACCTCTGCCTCCTGGCTGTGTTCAAGTGGTTCTGCTTCAGCCTCCCAAGTAGCTGGGGTTAGAGCACCCTGTCACCACGCCCCGCTAATTTTTGTATTTCTAGCAGAGATGAAGTTTCACTATGTTGGCCAGGCTGGGCTCAAACTCCTGACCTCAAGTGATCTGCCCGCCTTGGCCCCCCAAAGTGCTGTGATTACAGGCGTGAGCCGCCACGCCCAGCCTAATAAGGGTTTTAAAGATAATTAGTGTGTAGGTCTGTAGGCTTATGATGGTAACCACAAGTTGTTAATGGCATTGTGAAAAGTTTTTAGTTGCGCTTTATGGGTGGATGCTGAATTACATTTTGATTTGATACTTATAAAAAGAAAAAGTATTTCTTCAGCTTAAAAAATTGTTTAAAAGTTTGTGATCATATTGTCTACCATGTAGCCAGCTTTCAATTATATGTAAGAGGGACTTTTTGACATTTACAAATAATACTTTGAGGTAGATATCTGAAAGCACCAGCACTTGGAAGGTGTTCAGAAGTAACAAATTATAAAATGAGCTAACAAACGAAAGGCAAAATAAAACCGTAAAGCAAGCAGATGGGAGGCGTGTTCAGTAACTTATTCATAATGCATCTGAAATGATTGCTGTACTCAAATATTTAACGTTAGAGTAATAGTATTTTGAATGAAAACCATAGTTGATT</DNA_Seq>
  </Molecule_Seq>
  <Tissuelocal_List>
    <TissueLocal>
      <TissueLocal>Widely expressed</TissueLocal>
    </TissueLocal>
  </Tissuelocal_List>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cytoplasm</CellLocal>
      <Ontology_ID>GO:0005737</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Plasma membrane</CellLocal>
      <Ontology_ID>GO:0005886</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Nucleoplasm</CellLocal>
      <Ontology_ID>GO:0005654</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Nucleolus</CellLocal>
      <Ontology_ID>GO:0005730</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cytosol</CellLocal>
      <Ontology_ID>GO:0005829</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Endocytic vesicle membrane</CellLocal>
      <Ontology_ID>GO:0030666</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Nucleus</CellLocal>
      <Ontology_ID>GO:0005634</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Protein complex</CellLocal>
      <Ontology_ID>GO:0043234</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Insoluble fraction</CellLocal>
      <Ontology_ID>GO:0005626</Ontology_ID>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>MDM2</Gene_Name>
    <Gene_ID>4193</Gene_ID>
    <Genbank_ACCN>NM_002392</Genbank_ACCN>
    <Protein_ACCN>NP_002383</Protein_ACCN>
    <HGNC_ID>6973</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/4193</Gene_URL>
    <UCSC_ID>uc021rah.1</UCSC_ID>
    <EMBL_ID>ENSG00000135679</EMBL_ID>
  </Gene>
  <PPI_List>
    <PPI>
      <Uniprot_ID>Q8N9B5</Uniprot_ID>
      <Gene_Name>JMY</Gene_Name>
      <EBI_ID>EBI-866435</EBI_ID>
      <PPI_EBI_URL>EBI-389668,EBI-866435</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P68104</Uniprot_ID>
      <Gene_Name>EEF1A1</Gene_Name>
      <EBI_ID>EBI-352162</EBI_ID>
      <PPI_EBI_URL>EBI-389668,EBI-352162</PPI_EBI_URL>
      <Experiment_Number>6</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q9Y297</Uniprot_ID>
      <Gene_Name>BTRC</Gene_Name>
      <EBI_ID>EBI-307461</EBI_ID>
      <PPI_EBI_URL>EBI-389668,EBI-307461</PPI_EBI_URL>
      <Experiment_Number>9</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>O15297</Uniprot_ID>
      <Gene_Name>PPM1D</Gene_Name>
      <EBI_ID>EBI-1551512</EBI_ID>
      <PPI_EBI_URL>EBI-389668,EBI-1551512</PPI_EBI_URL>
      <Experiment_Number>4</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P48729</Uniprot_ID>
      <Gene_Name>CSNK1A1</Gene_Name>
      <EBI_ID>EBI-1383726</EBI_ID>
      <PPI_EBI_URL>EBI-389668,EBI-1383726</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q8N726</Uniprot_ID>
      <Gene_Name>CDKN2A</Gene_Name>
      <EBI_ID>EBI-625922</EBI_ID>
      <PPI_EBI_URL>EBI-389668,EBI-625922</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P06400</Uniprot_ID>
      <Gene_Name>RB1</Gene_Name>
      <EBI_ID>EBI-491274</EBI_ID>
      <PPI_EBI_URL>EBI-389668,EBI-491274</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P05412</Uniprot_ID>
      <Gene_Name>JUN</Gene_Name>
      <EBI_ID>EBI-852823</EBI_ID>
      <PPI_EBI_URL>EBI-389668,EBI-852823</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q93009</Uniprot_ID>
      <Gene_Name>USP7</Gene_Name>
      <EBI_ID>EBI-302474</EBI_ID>
      <PPI_EBI_URL>EBI-389668,EBI-302474</PPI_EBI_URL>
      <Experiment_Number>13</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q06486</Uniprot_ID>
      <Gene_Name>Csnk1d</Gene_Name>
      <EBI_ID>EBI-2910316</EBI_ID>
      <PPI_EBI_URL>EBI-389668,EBI-2910316</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q9BVP2</Uniprot_ID>
      <Gene_Name>GNL3</Gene_Name>
      <EBI_ID>EBI-641642</EBI_ID>
      <PPI_EBI_URL>EBI-389668,EBI-641642</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P49674</Uniprot_ID>
      <Gene_Name>CSNK1E</Gene_Name>
      <EBI_ID>EBI-749343</EBI_ID>
      <PPI_EBI_URL>EBI-389668,EBI-749343</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P04637</Uniprot_ID>
      <Gene_Name>TP53</Gene_Name>
      <EBI_ID>EBI-366083</EBI_ID>
      <PPI_EBI_URL>EBI-389668,EBI-366083</PPI_EBI_URL>
      <Experiment_Number>27</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q00987</Uniprot_ID>
      <Gene_Name>MDM2</Gene_Name>
      <EBI_ID>EBI-389668</EBI_ID>
      <PPI_EBI_URL>EBI-389668,EBI-389668</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q61937</Uniprot_ID>
      <Gene_Name>Npm1</Gene_Name>
      <EBI_ID>EBI-626362</EBI_ID>
      <PPI_EBI_URL>EBI-389668,EBI-626362</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P10275</Uniprot_ID>
      <Gene_Name>AR</Gene_Name>
      <EBI_ID>EBI-608057</EBI_ID>
      <PPI_EBI_URL>EBI-389668,EBI-608057</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q13616</Uniprot_ID>
      <Gene_Name>CUL1</Gene_Name>
      <EBI_ID>EBI-359390</EBI_ID>
      <PPI_EBI_URL>EBI-389668,EBI-359390</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P48729-2</Uniprot_ID>
      <Gene_Name>CSNK1A1</Gene_Name>
      <EBI_ID>EBI-2040168</EBI_ID>
      <PPI_EBI_URL>EBI-389668,EBI-2040168</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q9UKB1</Uniprot_ID>
      <Gene_Name>FBXW11</Gene_Name>
      <EBI_ID>EBI-355189</EBI_ID>
      <PPI_EBI_URL>EBI-389668,EBI-355189</PPI_EBI_URL>
      <Experiment_Number>4</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P62913</Uniprot_ID>
      <Gene_Name>RPL11</Gene_Name>
      <EBI_ID>EBI-354380</EBI_ID>
      <PPI_EBI_URL>EBI-389668,EBI-354380</PPI_EBI_URL>
      <Experiment_Number>6</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q9NVN8</Uniprot_ID>
      <Gene_Name>GNL3L</Gene_Name>
      <EBI_ID>EBI-746682</EBI_ID>
      <PPI_EBI_URL>EBI-389668,EBI-746682</PPI_EBI_URL>
      <Experiment_Number>8</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P06748</Uniprot_ID>
      <Gene_Name>NPM1</Gene_Name>
      <EBI_ID>EBI-78579</EBI_ID>
      <PPI_EBI_URL>EBI-389668,EBI-78579</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P15311</Uniprot_ID>
      <Gene_Name>EZR</Gene_Name>
      <EBI_ID>EBI-1056902</EBI_ID>
      <PPI_EBI_URL>EBI-389668,EBI-1056902</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P17535</Uniprot_ID>
      <Gene_Name>JUND</Gene_Name>
      <EBI_ID>EBI-2682803</EBI_ID>
      <PPI_EBI_URL>EBI-389668,EBI-2682803</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P62081</Uniprot_ID>
      <Gene_Name>RPS7</Gene_Name>
      <EBI_ID>EBI-354360</EBI_ID>
      <PPI_EBI_URL>EBI-389668,EBI-354360</PPI_EBI_URL>
      <Experiment_Number>15</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P29590</Uniprot_ID>
      <Gene_Name>PML</Gene_Name>
      <EBI_ID>EBI-295890</EBI_ID>
      <PPI_EBI_URL>EBI-389668,EBI-295890</PPI_EBI_URL>
      <Experiment_Number>6</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q9UER7</Uniprot_ID>
      <Gene_Name>DAXX</Gene_Name>
      <EBI_ID>EBI-77321</EBI_ID>
      <PPI_EBI_URL>EBI-389668,EBI-77321</PPI_EBI_URL>
      <Experiment_Number>14</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P19338</Uniprot_ID>
      <Gene_Name>NCL</Gene_Name>
      <EBI_ID>EBI-346967</EBI_ID>
      <PPI_EBI_URL>EBI-389668,EBI-346967</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P29590-5</Uniprot_ID>
      <Gene_Name>PML</Gene_Name>
      <EBI_ID>EBI-304008</EBI_ID>
      <PPI_EBI_URL>EBI-389668,EBI-304008</PPI_EBI_URL>
      <Experiment_Number>6</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q01105</Uniprot_ID>
      <Gene_Name>SET</Gene_Name>
      <EBI_ID>EBI-1053182</EBI_ID>
      <PPI_EBI_URL>EBI-389668,EBI-1053182</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P42677</Uniprot_ID>
      <Gene_Name>RPS27</Gene_Name>
      <EBI_ID>EBI-356336</EBI_ID>
      <PPI_EBI_URL>EBI-389668,EBI-356336</PPI_EBI_URL>
      <Experiment_Number>5</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P48730</Uniprot_ID>
      <Gene_Name>CSNK1D</Gene_Name>
      <EBI_ID>EBI-751621</EBI_ID>
      <PPI_EBI_URL>EBI-389668,EBI-751621</PPI_EBI_URL>
      <Experiment_Number>6</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q92736</Uniprot_ID>
      <Gene_Name>RYR2</Gene_Name>
      <EBI_ID>EBI-1170425</EBI_ID>
      <PPI_EBI_URL>EBI-389668,EBI-1170425</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>O15151</Uniprot_ID>
      <Gene_Name>MDM4</Gene_Name>
      <EBI_ID>EBI-398437</EBI_ID>
      <PPI_EBI_URL>EBI-389668,EBI-398437</PPI_EBI_URL>
      <Experiment_Number>5</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P03372</Uniprot_ID>
      <Gene_Name>ESR1</Gene_Name>
      <EBI_ID>EBI-78473</EBI_ID>
      <PPI_EBI_URL>EBI-389668,EBI-78473</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q71UM5</Uniprot_ID>
      <Gene_Name>RPS27L</Gene_Name>
      <EBI_ID>EBI-355126</EBI_ID>
      <PPI_EBI_URL>EBI-389668,EBI-355126</PPI_EBI_URL>
      <Experiment_Number>6</Experiment_Number>
    </PPI>
  </PPI_List>
  <Disease_List>
    <Disease>
      <Disease_Name>Breast Cancer</Disease_Name>
      <Disease_Detail>Breast Cancer</Disease_Detail>
      <Disease_DB>BRS047</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/breast_cancer?search=MDM2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Spindle Cell Lipoma</Disease_Name>
      <Disease_Detail>Spindle Cell Lipoma</Disease_Detail>
      <Disease_DB>SPN006</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/spindle_cell_lipoma?search=MDM2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Anaplastic Ependymoma</Disease_Name>
      <Disease_Detail>Anaplastic Ependymoma</Disease_Detail>
      <Disease_DB>ANP006</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/anaplastic_ependymoma?search=MDM2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Malignant Fibrous Histiocytoma of Bone</Disease_Name>
      <Disease_Detail>Malignant Fibrous Histiocytoma of Bone</Disease_Detail>
      <Disease_DB>MLG014</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/malignant_fibrous_histiocytoma_of_bone?search=MDM2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Accelerated Tumor Formation</Disease_Name>
      <Disease_Detail>Accelerated Tumor Formation</Disease_Detail>
      <Disease_DB>ACC008</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/accelerated_tumor_formation?search=MDM2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Meningioma</Disease_Name>
      <Disease_Detail>Meningioma</Disease_Detail>
      <Disease_DB>MNN012</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/meningioma?search=MDM2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Chondroma</Disease_Name>
      <Disease_Detail>Chondroma</Disease_Detail>
      <Disease_DB>CHN010</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/chondroma?search=MDM2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Peripheral Primitive Neuroectodermal Tumor</Disease_Name>
      <Disease_Detail>Peripheral Primitive Neuroectodermal Tumor</Disease_Detail>
      <Disease_DB>PRP025</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/peripheral_primitive_neuroectodermal_tumor?search=MDM2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Giant Cell Glioblastoma</Disease_Name>
      <Disease_Detail>Giant Cell Glioblastoma</Disease_Detail>
      <Disease_DB>GNT002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/giant_cell_glioblastoma?search=MDM2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Undifferentiated Embryonal Sarcoma of the Liver</Disease_Name>
      <Disease_Detail>Undifferentiated Embryonal Sarcoma of the Liver</Disease_Detail>
      <Disease_DB>UND001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/undifferentiated_embryonal_sarcoma_of_the_liver?search=MDM2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Congenital Mesoblastic Nephroma</Disease_Name>
      <Disease_Detail>Congenital Mesoblastic Nephroma</Disease_Detail>
      <Disease_DB>CNG029</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/congenital_mesoblastic_nephroma?search=MDM2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Histiocytoma</Disease_Name>
      <Disease_Detail>Histiocytoma</Disease_Detail>
      <Disease_DB>HST009</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/histiocytoma?search=MDM2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Li-Fraumeni Syndrome</Disease_Name>
      <Disease_Detail>Li-Fraumeni Syndrome</Disease_Detail>
      <Disease_DB>LFR001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/li_fraumeni_syndrome?search=MDM2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Atypical Lipomatous Tumor</Disease_Name>
      <Disease_Detail>Atypical Lipomatous Tumor</Disease_Detail>
      <Disease_DB>ATY008</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/atypical_lipomatous_tumor?search=MDM2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Male Germ Cell Tumor</Disease_Name>
      <Disease_Detail>Male Germ Cell Tumor</Disease_Detail>
      <Disease_DB>MLG083</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/male_germ_cell_tumor?search=MDM2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Ependymoma</Disease_Name>
      <Disease_Detail>Ependymoma</Disease_Detail>
      <Disease_DB>EPN002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/ependymoma?search=MDM2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Mesoblastic Nephroma</Disease_Name>
      <Disease_Detail>Mesoblastic Nephroma</Disease_Detail>
      <Disease_DB>MSB002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/mesoblastic_nephroma?search=MDM2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Acute Lymphoblastic Leukemia</Disease_Name>
      <Disease_Detail>Acute Lymphoblastic Leukemia</Disease_Detail>
      <Disease_DB>ACT101</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/acute_lymphoblastic_leukemia?search=MDM2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Oligodendroglioma</Disease_Name>
      <Disease_Detail>Oligodendroglioma</Disease_Detail>
      <Disease_DB>OLG002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/oligodendroglioma?search=MDM2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Glioblastoma</Disease_Name>
      <Disease_Detail>Glioblastoma</Disease_Detail>
      <Disease_DB>GLB002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/glioblastoma?search=MDM2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Retroperitoneal Sarcoma</Disease_Name>
      <Disease_Detail>Retroperitoneal Sarcoma</Disease_Detail>
      <Disease_DB>RTR010</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/retroperitoneal_sarcoma?search=MDM2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Adult Astrocytic Tumour</Disease_Name>
      <Disease_Detail>Adult Astrocytic Tumour</Disease_Detail>
      <Disease_DB>ADL053</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/adult_astrocytic_tumour?search=MDM2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Inflammatory Breast Carcinoma</Disease_Name>
      <Disease_Detail>Inflammatory Breast Carcinoma</Disease_Detail>
      <Disease_DB>INF023</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/inflammatory_breast_carcinoma?search=MDM2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Pleomorphic Xanthoastrocytoma</Disease_Name>
      <Disease_Detail>Pleomorphic Xanthoastrocytoma</Disease_Detail>
      <Disease_DB>PLM020</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/pleomorphic_xanthoastrocytoma?search=MDM2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Verrucous Carcinoma</Disease_Name>
      <Disease_Detail>Verrucous Carcinoma</Disease_Detail>
      <Disease_DB>VRR004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/verrucous_carcinoma?search=MDM2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Fibrous Histiocytoma</Disease_Name>
      <Disease_Detail>Fibrous Histiocytoma</Disease_Detail>
      <Disease_DB>FBR003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/fibrous_histiocytoma?search=MDM2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Cardia Cancer</Disease_Name>
      <Disease_Detail>Cardia Cancer</Disease_Detail>
      <Disease_DB>CRD005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/cardia_cancer?search=MDM2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Sapho Syndrome</Disease_Name>
      <Disease_Detail>Sapho Syndrome</Disease_Detail>
      <Disease_DB>SPH001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/sapho_syndrome?search=MDM2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Lipoma</Disease_Name>
      <Disease_Detail>Lipoma</Disease_Detail>
      <Disease_DB>LPM004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/lipoma?search=MDM2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Dedifferentiated Liposarcoma</Disease_Name>
      <Disease_Detail>Dedifferentiated Liposarcoma</Disease_Detail>
      <Disease_DB>DDF001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/dedifferentiated_liposarcoma?search=MDM2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Epithelioid Hemangioendothelioma</Disease_Name>
      <Disease_Detail>Epithelioid Hemangioendothelioma</Disease_Detail>
      <Disease_DB>EPT020</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/epithelioid_hemangioendothelioma?search=MDM2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Leiomyosarcoma</Disease_Name>
      <Disease_Detail>Leiomyosarcoma</Disease_Detail>
      <Disease_DB>LMY004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/leiomyosarcoma?search=MDM2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Anal Squamous Cell Carcinoma</Disease_Name>
      <Disease_Detail>Anal Squamous Cell Carcinoma</Disease_Detail>
      <Disease_DB>ANL017</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/anal_squamous_cell_carcinoma?search=MDM2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Retroperitoneal Fibrosis</Disease_Name>
      <Disease_Detail>Retroperitoneal Fibrosis</Disease_Detail>
      <Disease_DB>RTR011</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/retroperitoneal_fibrosis?search=MDM2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Osteosarcoma</Disease_Name>
      <Disease_Detail>Osteosarcoma</Disease_Detail>
      <Disease_DB>OST018</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/osteosarcoma?search=MDM2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hodgkin's Lymphoma</Disease_Name>
      <Disease_Detail>Hodgkin's Lymphoma</Disease_Detail>
      <Disease_DB>HDG007</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hodgkins_lymphoma?search=MDM2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Pleomorphic Liposarcoma</Disease_Name>
      <Disease_Detail>Pleomorphic Liposarcoma</Disease_Detail>
      <Disease_DB>PLM019</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/pleomorphic_liposarcoma?search=MDM2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Chromosome 5q Deletion</Disease_Name>
      <Disease_Detail>Chromosome 5q Deletion</Disease_Detail>
      <Disease_DB>CHR253</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/chromosome_5q_deletion?search=MDM2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Liposarcoma</Disease_Name>
      <Disease_Detail>Liposarcoma</Disease_Detail>
      <Disease_DB>LPS002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/liposarcoma?search=MDM2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Embryonal Sarcoma</Disease_Name>
      <Disease_Detail>Embryonal Cancer</Disease_Detail>
      <Disease_DB>EMB007</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/embryonal_sarcoma?search=MDM2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Familial Melanoma</Disease_Name>
      <Disease_Detail>Familial Melanoma</Disease_Detail>
      <Disease_DB>FML024</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/familial_melanoma?search=MDM2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Non-Hodgkin Lymphoma</Disease_Name>
      <Disease_Detail>Non-Hodgkin Lymphoma</Disease_Detail>
      <Disease_DB>NNH001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/non_hodgkin_lymphoma?search=MDM2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Gliomatosis Cerebri</Disease_Name>
      <Disease_Detail>Gliomatosis Cerebri</Disease_Detail>
      <Disease_DB>GLM004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/gliomatosis_cerebri?search=MDM2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Soft Tissue Sarcoma</Disease_Name>
      <Disease_Detail>Soft Tissue Sarcoma</Disease_Detail>
      <Disease_DB>SFT003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/soft_tissue_sarcoma?search=MDM2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Spindle Cell Liposarcoma</Disease_Name>
      <Disease_Detail>Spindle Cell Liposarcoma</Disease_Detail>
      <Disease_DB>SPN017</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/spindle_cell_liposarcoma?search=MDM2#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>MDM2 in complex with an 8-mer p53 peptide analogue</PDB_Title>
      <PDB_ID>2GV2</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2GV2</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystallographic Analysis of an 8-mer p53 Peptide Analogue Complexed with MDM2.</PubMed_Title>
      <Author>Sakurai, K., et al.</Author>
      <Journal>J.Am.Chem.Soc.(2006)128:11000-11001</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16925398?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>The Crystal Strucure of the N-terminal domain of HAUSP/USP7 complexed with mdm2 peptide 147-150</PDB_Title>
      <PDB_ID>2FOP</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2FOP</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Molecular recognition of p53 and MDM2 by USP7/HAUSP</PubMed_Title>
      <Author>Sheng, Y., et al.</Author>
      <Journal>Nat.Struct.Mol.Biol.(2006)13:285-291</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16474402?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>SOLUTION STRUCTURE OF THE C4 ZINC-FINGER DOMAIN OF HDM2</PDB_Title>
      <PDB_ID>2C6A</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2C6A</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Solution Structure of the C4 Zinc Finger Domain of Hdm2.</PubMed_Title>
      <Author>Yu, G.W., et al.</Author>
      <Journal>Protein Sci.(2006)15:384</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16385008?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF THE MDM2-MDMX RING DOMAIN HETERODIMER</PDB_Title>
      <PDB_ID>2VJF</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2VJF</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of the Mdm2/Mdmx Ring Domain Heterodimer Reveals Dimerization is Required for Their Ubiquitylation in Trans.</PubMed_Title>
      <Author>Linke, K., et al.</Author>
      <Journal>Cell Death Differ.(2008)15:841-848</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18219319?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human MDM2 in complex with a potent miniature protein inhibitor (18-residues)</PDB_Title>
      <PDB_ID>3IUX</PDB_ID>
      <Resolution>1.65</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3IUX</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Apamin as a template for structure-based rational design of potent peptide activators of p53.</PubMed_Title>
      <Author>Li, C., et al.</Author>
      <Journal>Angew.Chem.Int.Ed.Engl.(2009)48:8712-8715</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19827079?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>MDM2 BOUND TO THE TRANSACTIVATION DOMAIN OF P53</PDB_Title>
      <PDB_ID>1YCR</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1YCR</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.</PubMed_Title>
      <Author>Kussie, P.H., et al.</Author>
      <Journal>Science(1996)274:948-953</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/8875929?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human MDM2 liganded with a 12mer peptide inhibitor (pDI6W)</PDB_Title>
      <PDB_ID>3JZR</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3JZR</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure-based design of high affinity peptides inhibiting the interaction of p53 with MDM2 and MDMX.</PubMed_Title>
      <Author>Phan, J., et al.</Author>
      <Journal>J.Biol.Chem.(2010)285:2174-2183</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19910468?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure of human MDM2 in complex with high affinity peptide</PDB_Title>
      <PDB_ID>3G03</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3G03</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx</PubMed_Title>
      <Author>Czarna, A., et al.</Author>
      <Journal>Cell Cycle(2009)8:1176-1184</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19342883?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the TRAF-like domain of HAUSP/USP7 bound to a MDM2 peptide</PDB_Title>
      <PDB_ID>2F1Y</PDB_ID>
      <Resolution>1.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2F1Y</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural Basis of Competitive Recognition of p53 and MDM2 by HAUSP/USP7: Implications for the Regulation of the p53-MDM2 Pathway.</PubMed_Title>
      <Author>Hu, M., et al.</Author>
      <Journal>Plos Biol.(2006)4:e27-e27</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16402859?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure of human MDM2 in complex with an optimized p53 peptide</PDB_Title>
      <PDB_ID>1T4F</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1T4F</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells</PubMed_Title>
      <Author>Grasberger, B.L., et al.</Author>
      <Journal>J.Med.Chem.(2005)48:909-912</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15715460?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF HUMAN MDM2 WITH AN IMIDAZOLINE INHIBITOR</PDB_Title>
      <PDB_ID>1RV1</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1RV1</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.</PubMed_Title>
      <Author>Vassilev, L.T., et al.</Author>
      <Journal>Science(2004)303:844-848</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/14704432?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure of human MDM2 protein in complex with Mi-63-analog</PDB_Title>
      <PDB_ID>3LBL</PDB_ID>
      <Resolution>1.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3LBL</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Structure of the Stapled p53 Peptide Bound to Mdm2</PDB_Title>
      <PDB_ID>3V3B</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3V3B</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of the stapled p53 peptide bound to Mdm2.</PubMed_Title>
      <Author>Baek, S., et al.</Author>
      <Journal>J.Am.Chem.Soc.(2012)134:103-106</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/22148351?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>SOLUTION STRUCTURE OF THE C4 ZINC-FINGER DOMAIN OF HDM2</PDB_Title>
      <PDB_ID>2C6B</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2C6B</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Solution Structure of the C4 Zinc Finger Domain of Hdm2.</PubMed_Title>
      <Author>Yu, G.W., et al.</Author>
      <Journal>Protein Sci.(2006)15:384</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16385008?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human MDM2 liganded with a 12mer peptide inhibitor (pDIQ)</PDB_Title>
      <PDB_ID>3JZS</PDB_ID>
      <Resolution>1.78</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3JZS</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure-based design of high affinity peptides inhibiting the interaction of p53 with MDM2 and MDMX.</PubMed_Title>
      <Author>Phan, J., et al.</Author>
      <Journal>J.Biol.Chem.(2010)285:2174-2183</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19910468?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure of human MDM2 protein in complex with a small molecule inhibitor</PDB_Title>
      <PDB_ID>3LBK</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3LBK</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>NMR structure of unliganded MDM2</PDB_Title>
      <PDB_ID>1Z1M</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1Z1M</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of Free MDM2 N-terminal Domain Reveals Conformational Adjustments that Accompany p53-binding</PubMed_Title>
      <Author>Uhrinova, S., et al.</Author>
      <Journal>J.Mol.Biol.(2005)350:587-598</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15953616?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human MDM2 with a 12-mer peptide inhibitor PMI (N8A mutant)</PDB_Title>
      <PDB_ID>3LNZ</PDB_ID>
      <Resolution>1.95</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3LNZ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Systematic mutational analysis of peptide inhibition of the p53-MDM2/MDMX interactions.</PubMed_Title>
      <Author>Li, C., et al.</Author>
      <Journal>J.Mol.Biol.(2010)398:200-213</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20226197?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF THE MDM2-MDMX RING DOMAIN HETERODIMER</PDB_Title>
      <PDB_ID>2VJE</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2VJE</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of the Mdm2/Mdmx Ring Domain Heterodimer Reveals Dimerization is Required for Their Ubiquitylation in Trans.</PubMed_Title>
      <Author>Linke, K., et al.</Author>
      <Journal>Cell Death Differ.(2008)15:841-848</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18219319?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human MDM2 complexed with D-peptide (12 residues)</PDB_Title>
      <PDB_ID>3IWY</PDB_ID>
      <Resolution>1.93</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3IWY</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>D-peptide inhibitors of the p53-MDM2 interaction for targeted molecular therapy of malignant neoplasms.</PubMed_Title>
      <Author>Liu, M., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(2010)398:200-213</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20660730?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>crystal structure of MDM2 with chromenotriazolopyrimidine 1</PDB_Title>
      <PDB_ID>3JZK</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3JZK</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein interaction.</PubMed_Title>
      <Author>Allen, J.G., et al.</Author>
      <Journal>J.Med.Chem.(2009)52:7044-7053</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19856920?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HDM2 in complex with a beta-hairpin</PDB_Title>
      <PDB_ID>2AXI</PDB_ID>
      <Resolution>1.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2AXI</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure-Activity Studies in a Family of beta-Hairpin Protein Epitope Mimetic Inhibitors of the p53-HDM2 Protein-Protein Interaction.</PubMed_Title>
      <Author>Fasan, R., et al.</Author>
      <Journal>Chembiochem(2006)7:515-526</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16511824?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure of Human MDM2 in complex with a Benzodiazepine Inhibitor</PDB_Title>
      <PDB_ID>1T4E</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1T4E</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells</PubMed_Title>
      <Author>Grasberger, B.L., et al.</Author>
      <Journal>J.Med.Chem.(2005)48:909-912</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15715460?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human MDM2 in complex with D-peptide inhibitor (DPMI-alpha)</PDB_Title>
      <PDB_ID>3LNJ</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3LNJ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>A left-handed solution to peptide inhibition of the p53-MDM2 interaction.</PubMed_Title>
      <Author>Liu, M., et al.</Author>
      <Journal>Angew.Chem.Int.Ed.Engl.(2010)49:3649-3652</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20449836?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Solution Structure of Hdm2 RING Finger Domain</PDB_Title>
      <PDB_ID>2HDP</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2HDP</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Solution structure of the Hdm2 C2H2C4 RING, a domain critical for ubiquitination of p53.</PubMed_Title>
      <Author>Kostic, M., et al.</Author>
      <Journal>J.Mol.Biol.(2006)363:433-450</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16965791?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Exhaustive Fluorine Scanning towards Potent p53-MDM2 Antagonist</PDB_Title>
      <PDB_ID>3TU1</PDB_ID>
      <Resolution>1.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3TU1</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Exhaustive Fluorine Scanning toward Potent p53-Mdm2 Antagonists.</PubMed_Title>
      <Author>Huang, Y., et al.</Author>
      <Journal>Chemmedchem(2012)7:49-52</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21954050?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human MDM2 in complex with a 12-mer peptide inhibitor</PDB_Title>
      <PDB_ID>3EQS</PDB_ID>
      <Resolution>1.65</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3EQS</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX.</PubMed_Title>
      <Author>Pazgier, M., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(2009)106:4665-4670</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19255450?dopt=Abstract</PubMed_ID>
    </PDB>
  </PDB_List>
  <Network_List>
    <Network>
      <Pathway_ID>ko05220</Pathway_ID>
      <Pathway_Title>Chronic myeloid leukemia</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05215</Pathway_ID>
      <Pathway_Title>Prostate cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05205</Pathway_ID>
      <Pathway_Title>Proteoglycans in cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04919</Pathway_ID>
      <Pathway_Title>Thyroid hormone signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05214</Pathway_ID>
      <Pathway_Title>Glioma</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05200</Pathway_ID>
      <Pathway_Title>Pathways in cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04151</Pathway_ID>
      <Pathway_Title>PI3K-Akt signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05202</Pathway_ID>
      <Pathway_Title>Transcriptional misregulation in cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04115</Pathway_ID>
      <Pathway_Title>p53 signaling pathway</Pathway_Title>
      <Pathway_Class>Cellular Processes</Pathway_Class>
      <Pathway_Subclass>Cell growth and death</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05219</Pathway_ID>
      <Pathway_Title>Bladder cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05218</Pathway_ID>
      <Pathway_Title>Melanoma</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04068</Pathway_ID>
      <Pathway_Title>FoxO signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05203</Pathway_ID>
      <Pathway_Title>Viral carcinogenesis</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05169</Pathway_ID>
      <Pathway_Title>Epstein-Barr virus infection</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Infectious diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05206</Pathway_ID>
      <Pathway_Title>MicroRNAs in cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05220</Pathway_ID>
      <Pathway_Title>Chronic myeloid leukemia</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05206</Pathway_ID>
      <Pathway_Title>MicroRNAs in cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04110</Pathway_ID>
      <Pathway_Title>Cell cycle</Pathway_Title>
      <Pathway_Class>Cellular Processes</Pathway_Class>
      <Pathway_Subclass>Cell growth and death</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05200</Pathway_ID>
      <Pathway_Title>Pathways in cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04115</Pathway_ID>
      <Pathway_Title>p53 signaling pathway</Pathway_Title>
      <Pathway_Class>Cellular Processes</Pathway_Class>
      <Pathway_Subclass>Cell growth and death</Pathway_Subclass>
    </Network>
  </Network_List>
  <Fold>
    <SCOP_Class>All alpha proteins</SCOP_Class>
    <SCOP_URL>http://scop.mrc-lmb.cam.ac.uk/scop/data/scop.b.b.fi.b.b.c.html</SCOP_URL>
    <CATH_Class>Class 1: Mainly Alpha</CATH_Class>
    <CATH_URL>http://www.cathdb.info/pdb/1rv1</CATH_URL>
  </Fold>
  <Enzyme_Nomenclature_List>
    <Enzyme_Nomenclature>
      <Enzyme_DB_ID>6.3.2.-</Enzyme_DB_ID>
      <Enzyme_DB_URL>http://www.chem.qmul.ac.uk/iubmb/enzyme/EC6/3/2/-.html</Enzyme_DB_URL>
    </Enzyme_Nomenclature>
  </Enzyme_Nomenclature_List>
  <Create_Date>2012-06-20</Create_Date>
</Organism_Record>